Pretreatment prostate-specific antigen velocity and the risk of death from prostate cancer in the individual with low-risk prostate cancer.

摘要

Evaluating the ability of a new prognostic factor to predict cancer-specific outcomes for an individual stands in contradistinction to an assessment of whether the prediction of these outcomes improves when the new prognostic factor is analyzed with a known prognostic factor in a population of men with heterogeneous cancer-based risk profiles. Specifically for the case of the individual with localized prostate cancer, several studies1"3 have shown that a prostate-specific antigen (PSA) velocity higher than 2 ng/mL/year has a clinically important impact on the risk of prostate cancer-specific mortality after either radical prostatectomy or external-beam radiation therapy if that man has otherwise favorable known prognostic factors (ie, low-risk prostate cancer with a PSA < 10 ng/mL, biopsy Gleason score 6 or lower, and clinical tumor category lc or 2a)